

07

UPDATE

New Zealand Pharmaceutical Schedule

Effective 1 September 2007

Section H cumulative for August and September 2007

Investing in Health

PHARMAC
Pharmaceutical Management Agency

Contents

Summary of PHARMAC decisions - effective 1 September 2007.....	3
Antibiotics campaign - check it out.....	4
Campaign addresses high use of proton pump inhibitors.....	5
Update on Betaloc CR and Plendil ER.....	6
More ondansetron tablets per prescription.....	6
Further medicines for pain subsidised.....	7
Tender News.....	8
Looking Forward.....	9
Sole Subsidised Supply products cumulative to September 2007.....	12
New Listings.....	19
Changes to Restrictions.....	20
Changes to Subsidy and Manufacturer's Price.....	21
Changes to Section G: Safety Cap Medicines.....	21
Changes to Sole Subsidised Supply.....	21
Delisted Items.....	22
Items to be Delisted.....	24
Section H changes to Part II.....	25
Index.....	27

Summary of PHARMAC decisions

EFFECTIVE 1 SEPTEMBER 2007

New listing (page 19)

- Azithromycin (Arrow-Azithromycin) tab 500 mg – Maximum of 2 tab per prescription, endorsement criteria, available on a PSO
- Methadone hydrochloride (PSM) tab 5 mg – only on a controlled drug form, no patient co-payment payable
- Oxycodone hydrochloride (OxyNorm) inj 10 mg per ml, 1 ml and 2 ml, and oral liq 5 mg per 5 ml – only on a controlled drug form, no patient co-payment payable

Changes to restriction (page 20)

- Ondansetron – addition of Special Authority criteria to waive quantity restriction

Increased subsidy (page 21)

- Hydrocortisone butyrate (Locoid) scalp lotn 0.1%, 100 ml OP
- Nitrofurantoin (Nifuran) tab 50 mg and 100mg
- Lithium carbonate (Priadel) tab long-acting 400 mg
- Phenylephrine hydrochloride (Prefrin) eye drops 0.12%

Decreased subsidy (page 21)

- Metformin hydrochloride (Metomin) tab 500 mg and 850 mg
- Water (AstraZeneca) purified for inj 5 ml and 10 ml
- Malathion (AFT) liq 0.5%

Antibiotics campaign – check it out



Wise Use of Antibiotics is the longest-running of PHARMAC's 'Demand-Side' activities and is now into its 10th year. It is supported by pharmacists (through the Pharmaceutical Society and Pharmacy Guild), Plunket and the Royal New Zealand College of GPs.

The campaign has been successful in raising awareness about how to use antibiotics appropriately, and we have seen prescription numbers for broad spectrum antibiotics (those most commonly prescribed for respiratory infections), come down and stay down. To continue this success we need to continue to be vigilant and ensure antibiotics are prescribed for the right people, and used well.

The need for the campaign is no less now than it was then. Arguably, with increasing levels of bacterial resistance around the world and few new antibacterial agents being brought to market, the need is greater than ever.

But attitudes are slowly changing. In a survey run for us by Colmar Brunton, 53% of people expected to receive an antibiotic when they visited their doctor, compared with 59% the previous year and 79% the year before that. In line with this reduced expectation, there was a continuing decrease in the number of people who received antibiotics – down to 58% from 69% the previous year.

Also in the survey, nine out of 10 people agreed that the best treatment for colds and flu is rest and drinking fluids.

In 2007 the campaign has promoted three key messages:

- **Antibiotics don't do colds and flu**
- **If in doubt check it out**

And if you do need an antibiotic

- **Take the lot no matter what.**

This year also saw the advent of a set of computer-animated television advertisements, which bring to life the images on the posters and brochures that have been distributed to pharmacies and GP surgeries around the country. These ads were run during July and we plan to use them again, perhaps with some minor changes following feedback, next year as well.



Campaign addresses high use of proton pump inhibitors

Proton pump inhibitors are one of the pharmaceutical success stories of the past decade and are now some of the most-prescribed medicines in New Zealand.

At any one time, we estimate up to 250,000 New Zealanders might be prescribed a PPI. Omeprazole (Losec) alone accounts for some 950,000 prescriptions a year and rising, making it the third-most prescribed medicine in the country.

Used well, PPIs are a valuable medicine to have in treating gastro-intestinal disorders, peptic ulcers and dyspepsia. PPIs are generally regarded as safe and effective for long term and intermittent treatment.

However, they are expensive relative to some other medicines (like H2 antagonists) that do much the same thing, and may be used unnecessarily to treat patients with only mild dyspepsia.

That's why we have been developing the Gut Reaction campaign in collaboration with a range of organisations including the College of Pharmacists, Pharmacy Guild, Pharmaceutical Society, NZ Gastroenterology Society executive, New Zealand Guidelines Group, BPAC and the DHBNZ/PHO team.

Gut Reaction aims to encourage prescribing of PPIs only for those patients whose conditions merit them.

A significant number of people are using PPIs long-term (longer than six months) when they don't need to, or when they could make lifestyle changes to manage symptoms.

Over the counter products, or medicines like H2 antagonists (such as ranitidine) may be more appropriate for the patient. Like other PHARMAC campaigns, Gut Reaction is aimed at ensuring optimal use is made of these medicines.

The campaign is underpinned by a statement endorsed by the NZ Gastroenterology Society that:

“It is recommended that within three months of initiation of treatment with a PPI, patient’s regimen be reviewed with the aim of reducing the dose and/or initiation of an alternative treatment option where clinically appropriate.”

In the first phase of the campaign, we worked with the College of Pharmacists to develop a pack to help pharmacists work through a review of PPI prescribing with patients. Pharmacists were asked to identify and review patients who had been prescribed PPIs at least twice in the past six months.

We're now developing the campaign with information for GPs and primary health nurses, and hospital pharmacies. A consumer-focussed website is also being developed.



Update on Betaloc CR and Plendil ER

AstraZeneca has provided notification of its intention to raise the price of Betaloc CR and Plendil ER 2.5mg. This may lead to a manufacturer's surcharge applying to these medicines. AstraZeneca's price increase is due to take effect on 12 September (i.e. reflected in the 1 October Pharmaceutical Schedule).


We've taken on board feedback about the risks to some patients facing a surcharge. We have made arrangements to allow those patients to continue to have fully subsidized Betaloc CR. To make this happen, Betaloc CR will be fully funded under endorsement for the following patient groups from 1 October:

- Heart failure;
- Angina;
- Heart Rate Control; and
- Post-Myocardial Infarction.

To help GPs and pharmacists, we have also commissioned BPACNZ to develop material to help manage patients who may decide to change to a fully-funded medicine, should a surcharge apply. Information has been completed and will be circulated to General Practitioners and Pharmacists should a price increase occur.

Other actions we have taken to help health professionals manage patients include:

- Listed isradipine to provide an alternative low dose CCB to Plendil ER 2.5mg;
- Removed the Special Authority applying to carvedilol to provide an alternative to Betaloc CR;



- Fully funding metoprolol tartrate 50 mg tablets from 1 October; and
- Fully funding repeats for prescriptions for Plendil ER 2.5 or Betaloc CR that were initially dispensed prior to 1 October.

Betaloc injection - AstraZeneca has advised that the currently listed metoprolol tartrate injection 1 mg per ml, 5 ml (Betaloc) remains available.

More ondansetron tablets per prescription

Greater access is being provided to the anti-nausea drug ondansetron for some cancer patients undergoing chemotherapy. The changes apply specifically to patients undergoing prolonged highly emetogenic chemotherapy and/or radiation therapy.

Under the changes, patients meeting the new Special Authority criteria for ondansetron tablets will not be restricted to the current maximum number of tablets per prescription or dispensing from 1 September 2007. See page 20 for the full Special Authority criteria.

Further medicines for pain subsidised

Two new presentations of oxycodone products used to treat pain will be subsidised from 1 September 2007. OxyNorm (oxycodone hydrochloride) injections 10 mg per ml, 1 ml and 2 ml ampoules, and oral liquid 5 mg per 5 ml will be subsidised without restriction.

Oxycodone is a strong opioid analgesic similar to morphine, and is used to treat opioid-responsive moderate to severe pain.

As with all Class B controlled drugs, oxycodone hydrochloride needs to be prescribed on a triplicate controlled drug prescription form for a maximum of one month supply. It can only be dispensed in ten day lots. There is no patient co-payment required for these presentations.



Are you interested?

Resources are now available for you to order.

Fax your details to 0800 gut info (0800 488 4636).

For further information go to WWW.gutreaction.co.nz

This campaign supports recommended prescribing practice which is set out in the New Zealand Guidelines and aims to promote the responsible use of medications for this particular therapy area.

Tender News

Sole Subsidised Supply changes – effective 1 October 2007

Chemical Name	Presentation; Pack size	Sole Subsidised Supply brand (and supplier)
Amoxicillin	Cap 250 mg; 500 cap	Apo-Amoxi (Aptex)
Amoxicillin	Cap 500 mg; 500 cap	Apo-Amoxi (Aptex)
Bisacodyl	Tab 5 mg; 200 tab	Lax-Tabs (AFT)
Cefaclor monohydrate	Cap 250 mg; 100 cap	Ranbaxy-Cefaclor (Douglas)
Cefaclor monohydrate	Grans for oral liq 125 mg per 5 ml; 100 ml	Ranbaxy-Cefaclor (Douglas)
Clarithromycin	Grans for oral liquid 125 mg per 5 ml; 70 ml	Klacid (Abbott)
Clotrimazole	Vaginal crm 1% with applicator(s); 35 g OP	Clomazol (Multichem)
Colchicine	Tab 500 µg; 100 tab	Colgout (Aspen)
Compound electrolytes	Powder for soln for oral use; 10 sachet	Enerlyte (Multichem)
Desferrioxamine mesylate	Inj 500 mg; 10 inj	Mayne (Mayne)
Fluocortolone caproate with fluocortolone pivalate and cinchocaine	Oint 950 µg, with fluocortolone pivalate 920 µg, and cinchocaine hydrochloride 5 mg per g; 30 g OP	Ultraproct (CSL)
Fluocortolone caproate with fluocortolone pivalate and cinchocaine	Suppos 630 µg, with fluocortolone pivalate 610 µg, and cinchocaine hydrochloride 1 mg; 12 suppos	Ultraproct (CSL)
Fusidic acid	Crn 2%; 15 g OP	Foban (AFT)
Fusidic acid	Oint 2%; 15 g OP	Foban (AFT)
Haloperidol	Oral liq 2 mg per ml; 100 ml	Serenace (Sigma)
Haloperidol	Tab 500 µg; 100 tab	Serenace (Sigma)
Haloperidol	Tab 1.5 mg; 100 tab	Serenace (Sigma)
Haloperidol	Tab 5 mg; 100 tab	Serenace (Sigma)
Ipratropium bromide	Nebuliser soln, 250 µg per ml, 1 ml; 20 neb	Ipratropium Steri-Neb (Airflow)
Ipratropium bromide	Nebuliser soln, 250 µg per ml, 2 ml; 20 neb	Ipratropium Steri-Neb (Airflow)
Lignocaine hydrochloride	Inj 0.5%, 5 ml; 50 inj	Xylocaine (AstraZeneca)
Lignocaine hydrochloride	Inj 1%, 5 ml; 50 inj	Xylocaine (AstraZeneca)
Lignocaine hydrochloride	Inj 1%, 20 ml; 5 inj	Xylocaine (AstraZeneca)
Lignocaine with prilocaine	Crn 2.5% with prilocaine 2.5%; 30 g OP	EMLA (AstraZeneca)
Lignocaine with prilocaine	Crn 2.5% with prilocaine 2.5%, 5 g ; 5 tube	EMLA (AstraZeneca)
Loperamide hydrochloride	Tab 2 mg; 400 tab	Nodia (Multichem)
Loratadine	Oral liq 1 mg per ml, 100 ml	Lorapaed (AFT)
Maldison	Shampoo 1%; 30 ml OP	A-Lices (AFT)
Medroxyprogesterone acetate	Tab 2.5 mg; 30 tab	Provera (Pfizer)
Medroxyprogesterone acetate	Tab 5 mg; 100 tab	Provera (Pfizer)

Sole Subsidised Supply changes – effective 1 October 2007 (continued)

Chemical Name	Presentation; Pack size	Sole Subsidised Supply brand (and supplier)
Medroxyprogesterone acetate	Tab 10 mg; 30 tab	Provera (Pfizer)
Medroxyprogesterone acetate	Tab 100 mg; 100 tab	Provera (Pfizer)
Medroxyprogesterone acetate	Tab 200 mg; 30 tab	Provera (Pfizer)
Nadolol	Tab 40 mg; 100 tab	Apo-Nadolol (Apotex)
Nadolol	Tab 80 mg; 100 tab	Apo-Nadolol (Apotex)
Naltrexone hydrochloride	Tab 50 mg; 30 tab	ReVia (BMS)
Neostigmine	Inj 2.5 mg per ml, 1 ml; 50 inj	AstraZeneca (AstraZeneca)
Nystatin	Cap 500,000 u; 50 cap	Nilstat (Sigma)
Nystatin	Tab 500,000 u; 50 tab	Nilstat (Sigma)
Paraffin liquid with soft white paraffin	Eye oint with soft white paraffin; 3.5 g OP	Lacri-Lube (Allergan)
Phenoxymethylpenicillin (Penicillin V)	Cap potassium salt 250 mg; 50 cap	Cilicaine VK (Sigma)
Phenoxymethylpenicillin (Penicillin V)	Cap potassium salt 500 mg; 50 cap	Cilicaine VK (Sigma)
Rifabutin	Cap 150 mg; 30 cap	Mycobutin (Pfizer)
Salbutamol	Nebuliser soln 1 mg per ml, 2.5 ml; 20 neb	Asthalin (Rex)
Salbutamol	Nebuliser soln 2 mg per ml, 2.5 ml; 20 neb	Asthalin (Rex)
Salbutamol	Oral liq 2 mg per 5 ml; 150 ml	Salapin (AFT)
Sodium citro-tartrate	Grans eff 4 g sachets; 28 sachet	Ural (Arrow)
Syrup (pharmaceutical grade)	Liq; 2,000 ml	Midwest (Midwest)

Looking Forward

This section is designed to alert both pharmacists and prescribers to possible future changes. It may assist pharmacists to manage stock levels and keep prescribers up-to-date with proposals to change the Pharmaceutical Schedule.

Possible decisions for implementation 1 October 2007

- Aciclovir (Zovirax) eye oint 3% - removal of Retail pharmacy-Specialist restriction
- Atorvastatin (Lipitor) tab 10 mg, 20 mg and 40 mg – amended Special Authority criteria
- Betaxolol hydrochloride eye drops 0.25% (Betoptic S) and 0.5% (Betoptic) - removal of Retail pharmacy-Specialist restriction
- Brimonidine tartrate (AFT and Alphagan) eye drops 0.2% - removal of Retail pharmacy-Specialist restriction

Possible decisions for implementation 1 October 2007 (continued)

- Brimonidine tartrate with timolol maleate (Combigan) eye drops 0.2% with timolol maleate 0.5% - removal of Retail pharmacy-Specialist restriction
- Ciprofloxacin (Ciloxan) eye drops 0.3% - removal of Retail pharmacy-Specialist and Specialist must be an ophthalmologist restrictions
- Citalopram hydrobromide (Citalopram – Rex) tab 20 mg – new listing
- Dexamethasone (Maxidex) eye oint 0.1% and eye drops 0.1% - removal of Retail pharmacy-Specialist restriction
- Dexamethasone with framycetin and gramicidin (Sofradex) ear/eye drops 500 µg with framycetin sulphate 5 mg and gramicidin 50 µg per ml - removal of Retail pharmacy-Specialist when used in the treatment of eye conditions restriction
- Dexamethasone with neomycin and polymyxin B sulphate (Maxitrol) eye oint and eye drops - removal of Retail pharmacy-Specialist restriction
- Diclofenac sodium (Voltaren Ophtha) eye drops 1 mg per ml - removal of Retail pharmacy-Specialist restriction
- Dorzolamide hydrochloride (Trusopt) eye drops 2% - removal of Retail pharmacy-Specialist restriction
- Dorzolamide hydrochloride with timolol maleate (Cosopt) eye drops 2% with timolol maleate 0.5% - removal of Retail pharmacy-Specialist restriction
- Ezetimibe (Ezetrol) tab 10 mg – amended Special Authority criteria
- Ezetimibe with simvastatin (Vytorin) tab all strengths – amended Special Authority criteria
- Fat modules (Calogen, Liquigen & MCT Oil) – amended Special Authority criteria
- Fluorometholone (Flucon) eye drops 0.1% - removal of Retail pharmacy-Specialist restriction
- Gentamicin sulphate (Genoptic) eye drops 0.3% - removal of Retail pharmacy-Specialist restriction
- Levobunolol (Betagan) eye drops 0.25% and 0.5% - removal of Retail pharmacy-Specialist restriction
- Macrogol 3350 with sodium chloride, sodium bicarbonate and potassium chloride (Movicol) powder 13.125 g with sodium chloride 350.7 mg, sodium bicarbonate 178.5 mg and potassium chloride 46.6 mg – Special Authority – Retail pharmacy – not more than 60 x sachets per prescription
- Mesalazine (Asacol) tab 400 mg and suppos 500 mg – subsidy decrease
- Mesalazine (Pentasa) suppos 1 g – new listing
- Metoprolol tartrate (Lopresor) tab 50 mg – subsidy increase

Possible decisions for implementation 1 October 2007 (continued)

- Midazolam (Pfizer) inj 1 mg per ml, 5 ml and 5 mg per ml, 3 ml – new listing with manufacturer’s surcharge
- Omeprazole (Dr Reddy’s Omeprazole) cap 10 mg, 20 mg and 40 mg – new listing
- Paediatric products (Fortini, Fortini Multifibre, Nutrini RTH, Nutrini Energy RTH, PediaSure, PediaSure RTH, & Resource Just for Kids) – amended Special Authority criteria
- Pilocarpine (Minims) eye drops 2% single dose –Special Authority applicant type to “relevant practitioner” previously it was “medical practitioner.”
- Povidone iodine (Betadine) oint 10%, 25 g OP – price decrease
- Prednisolone acetate eye drops 0.12% (Pred Mild) and 1% (Pred Forte) - removal of Retail pharmacy-Specialist restriction
- Quetiapine (Quetapel) tab 25 mg, 100 mg, 200 mg and 300 mg – new listing
- Simvastatin (SimvaRex) tab 10 mg, 20 mg and 40 mg – new listing
- Timolol maleate eye drops 0.25% and 0.5% (Apo-Timop) and eye drops gel forming 0.25% and 0.5% (Timoptol XE) - removal of Retail pharmacy-Specialist restriction
- Tobramycin (Tobrex) eye oint 0.3% and eye drops 0.3% - removal of Retail pharmacy-Specialist restriction

Sole Subsidised Supply Products – cumulative to September 2007

Generic Name	Presentation	Brand Name	Expiry Date*
Acetazolamide	Tab 250 mg	Diamox	2008
Acipimox	Cap 250 mg	Olbetam	2008
Acitretin	Cap 10 mg & 25 mg	Neotigason	2008
Allopurinol	Tab 100 mg & 300 mg	Progout	2008
Amitriptyline	Tab 10 mg, 25 mg & 50 mg	Amitrip	2008
Amlodipine	Tab 5 mg & 10 mg	Calvasc	2008
Apomorphine hydrochloride	Inj 10 mg per ml, 1 ml	Mayne	2009
Amoxicillin	Grans for oral liq 125 mg per 5 ml	Ranbaxy Amoxicillin	2009
	Grans for oral liq 250 mg per 5 ml	Ranbaxy Amoxicillin	
	Inj 250 mg, 500 mg & 1 g	Ibiamox	2008
Applicator	Device	Ortho	2008
Aqueous cream	Cream	Multichem	2008
Ascorbic acid	Tab 100 mg	Apo-Ascorbic Acid	2009
Atenolol	Tab 50 mg & 100 mg	Loten	2009
Atropine sulphate	Inj 600 µg, 1 ml	AstraZeneca	2009
	Inj 1200 µg, 1 ml	AstraZeneca	
	Eye drops 1%	Atropt	2008
Beclomethasone dipropionate	Metered aqueous nasal spray 50 µg	Alanase	2009
	Metered aqueous nasal spray 100 µg	Alanase	
Betamethasone valerate	Scalp app 0.1%	Beta Scalp	2009
	Crn 0.1%	Beta Cream	2008
	Oint 0.1%	Beta Ointment	
Bezafibrate	Tab 200 mg	Fibalip	2008
Brimonidine tartrate	Eye drops 0.2%	AFT	2008
Bromocriptine mesylate	Tab 2.5 mg & 10 mg	Alpha-Bromocriptine	2008
Bupivacaine hydrochloride	Inj 0.5%, 4 ml	Marcain Isobaric	2010
	Inj 0.5%, 8% glucose, 4 ml	Marcain Heavy	
Calamine	Lotion BP	ABM	2009
	Crn, aqueous, BP	ABM	
Calcitriol	Cap 0.25 µg & 0.5 µg	Calcitriol-AFT	2009
Calcium carbonate	Tab dispersible 2.5 g	Calci-Tab Effervescent	2008
	Tab 1.25 g	Calci-Tab 500	
	Tab 1.5 g	Calci-Tab 600	
Calcium folinate	Inj 50 mg	Calcium Folate Ebewe	2008
Cefazolin sodium	Inj 500 mg & 1 g	m-Cefazolin	2008
Ceftriaxone sodium	Inj 500 mg & 1 g	AFT	2008
Cetirizine hydrochloride	Oral liq 1 mg per ml	Allerid C	2008
	Tab 10 mg	Razene	

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to September 2007

Generic Name	Presentation	Brand Name	Expiry Date*
Chloramphenicol	Eye drops 0.5% Eye oint 1%	Chlorsig Chlorsig	2009
Chlorhexidine gluconate	Handrub 1% with ethanol 70%	Orion	2009
	Mouthwash 0.2%	Orion	2008
	Soln 4%	Orion	
Chlorthalidone	Tab 25 mg	Hygroton	2009
Ciprofloxacin	Tab 250 mg, 500 mg & 750 mg	Cipflox	2008
Clindamycin	Cap hydrochloride 150 mg	Dalacin C	2008
	Inj phosphate 150 mg per ml, 4 ml		
Clobetasol propionate	Crn 0.05%	Dermol	2009
	Scalp app 0.05%	Dermol	2008
	Oint 0.05%	Dermol	
Clonazepam	Tab 500 µg & 2 mg	Paxam	2008
Clonidine	TDDS 2.5 mg, 100 µg per day	Catapres-TTS-1	2008
	TDDS 5 mg, 200 µg per day	Catapres-TTS-2	
	TDDS 7.5 mg, 300 µg per day	Catapres-TTS-3	
Clonidine hydrochloride	Tab 25 µg	Dixarit	2008
	Tab 150 µg	Catapres	
	Inj 150 µg per ml, 1 ml	Catapres	
Clotrimazole	Crn 1%	Clomazol	2008
Co-trimoxazole	Oral liq sugar-free trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml	Trisul	2008
	Tab trimethoprim 80 mg and sulphamethoxazole 400 mg		
Cyclizine hydrochloride	Tab 50 mg	Nausicalm	2009
Cyclizine lactate	Inj 50 mg per ml, 1 ml	Valoid (AFT)	2008
Cyclophosphamide	Tab 50 mg	Cycloblastin	2010
Cyproterone acetate	Tab 50 mg	Siterone	2009
Dantrolene sodium	Cap 25 mg & 50 mg	Dantrium	2009
Desmopressin	Nasal spray 10 µg per dose	Desmopressin-PH&T	2008
Dexamethasone sodium phosphate	Inj 4 mg per ml, 1 ml	Mayne	2009
	Inj 4 mg per ml, 2 ml		
Diaphragm	Range of sizes	Ortho All-flex & Ortho Coil	2008
Diclofenac sodium	Tab EC 25 mg & 50 mg	Apo-Diclo	2009
	Tab long-acting 75 mg & 100 mg	Apo-Diclo SR	
Didanosine (DDI)	Cap 125 mg, 200 mg, 250 mg & 400 mg	Videx EC	2009
Dihydrocodeine tartrate	Tab long-acting 60 mg	DHC Continus	2008

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to September 2007

Generic Name	Presentation	Brand Name	Expiry Date*
Diphenoxylate hydrochloride with atropine sulphate	Tab 2.5 mg with atropine sulphate 25 µg	Diastop	2008
Dipyridamole	Tab long-acting 150 mg	Pytazen SR	2008
Docusate sodium	Tab 50 mg & 120 mg	Coloxyl	2008
Emulsifying ointment BP	Ointment	AFT	2008
Enalapril	Tab 5 mg, 10 mg & 20 mg	m-Enalapril	2009
Ergometrine maleate	Inj 500 µg per ml, 1 ml	Mayne	2009
Ergotamine tartrate with caffeine	Tab 1 mg with caffeine 100 mg	Cafergot	2009
Erythromycin ethyl succinate	Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml	E-Mycin E-Mycin	2008
Ethambutol hydrochloride	Tab 400 mg	Myambutol	2008
Ethinylestradiol	Tab 10 µg	New Zealand Medical and Scientific	2009
Ethinylestradiol with norethisterone	Tab 35 µg with norethisterone 500 µg	Brevinor 21	2010
	Tab 35 µg with norethisterone 1 mg and 7 inert tab	Brevinor 1/21 Brevinor 1/28	
	Tab 35 µg with norethisterone 500 µg and 7 inert tab	Norimin	2008
Etoposide	Cap 50 mg & 100 mg	Vepesid	2009
Flucloxacillin sodium	Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml	Staphlex AFT AFT	2009
Fluconazole	Cap 50 mg, 150 mg & 200 mg	Pacific	2008
Fluorometholone	Eye drops 0.1%	Flucon	2009
Fluphenazine decanoate	Inj 12.5 mg per 0.5 ml, 0.5 ml Inj 25 mg per ml, 1 ml Inj 100 mg per ml, 1 ml	Modecate Modecate Modecate	2008
Folic Acid	Tab 0.8 mg & 5 mg	Apo-Folic Acid	2009
Gentamicin sulphate	Inj 40 mg per ml, 2 ml	Pfizer	2009
Gliclazide	Tab 80 mg	Apo-Gliclazide	2008
Glipizide	Tab 5 mg	Minidiab	2008
Haloperidol	Inj 5 mg per ml, 1 ml	Serenace	2009
Haloperidol decanoate	Inj 50 mg per ml, 1 ml Inj 100 mg per ml, 1 ml	Haldol Haldol Concentrate	2008
Heparinised saline	Inj 10 iu per ml, 5 ml	AstraZeneca	2009
Hydrocortisone	Tab 5 mg & 20 mg Powder 25 g	Douglas m-Hydrocortisone	2009 2008

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to September 2007

Generic Name	Presentation	Brand Name	Expiry Date*
Hydrocortisone acetate	Rectal foam 10%, CFC-Free	Colifoam	2009
Hydrocortisone with wool fat and mineral oil	Lotn 1% with wool fat hydrous 3% and mineral oil	DP Lotn HC	2008
Hyoscine N-butylbromide	Tab 10 mg Inj 20 mg	Gastrosoothe Buscopan	2008
Hypromellose	Eye drops 0.3% Eye drops 0.5%	Poly-Tears Methopt	2008
Ibuprofen	Tab 200 mg	I-Profen	2008
Imipramine hydrochloride	Tab 10 mg & 25 mg	Tofranil	2009
Indapamide	Tab 2.5 mg	Napamide	2009
Indomethacin	Cap 25 mg & 50 mg	Rheumacin	2008
Ipratropium bromide	Aerosol inhaler, 20 µg per dose CFC-free	Atrovent	2008
Isosorbide mononitrate	Tab long-acting 60 mg	Duride	2009
Isotretinoin	Cap 10 mg Cap 20 mg	Isotane 10 Isotane 20	2009
Itraconazole	Cap 100 mg	Sporanox	2010
Ketoconazole	Shampoo 2%	Ketopine	2008
Levobunolol	Eye drops 0.25% & 0.5%	Betagan	2010
Levodopa with benserazide	Cap 50 mg with benserazide 12.5 mg Tab dispersible 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg Cap long-acting 100 mg with benserazide 25 mg Cap 200 mg with benserazide 50 mg	Madopar 62.5 Madopar Dispersible Madopar 125 Madopar HBS Madopar 250	2009
Lisinopril	Tab 5 mg, 10 mg & 20 mg	Arrow-Lisinopril	2009
Lorazepam	Tab 1 mg & 2.5 mg	Ativan	2009
Magnesium sulphate	Inj 49.3%	Mayne	2009
Maprotiline hydrochloride	Tab 25 mg & 75 mg	Ludiomil	2009
Mesalazine	Enema 1 g per 100 ml	Pentasa	2009
Methadone hydrochloride	Powder 1 g	AFT	2009
Methodrexate	Tab 2.5 mg & 10 mg Inj 100 mg per ml, 5 ml Inj 100 mg per ml, 10 ml Inj 100 mg per ml, 50 ml	Methoblastin Methotrexate Ebewe Methotrexate Ebewe Methotrexate Ebewe	2009 2008
Methyldopa	Tab 125 mg, 250 mg & 500 mg	Prodopa	2008
Methylphenidate hydrochloride	Tab long-acting 20 mg Tab 5 mg & 20 mg Tab 10 mg	Rubifen SR Rubifen Rubifen	2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to September 2007

Generic Name	Presentation	Brand Name	Expiry Date*
Methylprednisolone	Tab 4 mg & 100 mg	Medrol	2009
Methylprednisolone aceponate	Crn 0.1% and oint 0.1%	Advantan	2009
Methylprednisolone acetate	Inj 40 mg per ml, 1 ml	Depo-Medrol	2008
Methylprednisolone acetate with lignocaine	Inj 40 mg per ml with lignocaine 1 ml	Depo-Medrol with Lidocaine	2008
Methylprednisolone sodium succinate	Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 1 ml Inj 500 mg & 1 g	Solu-Medrol Solu-Medrol Solu-Medrol	2009
Metoclopramide hydrochloride	Inj 5 mg per ml, 2 ml	Pfizer	2008
Metoprolol tartrate	Tab long-acting 200 mg	Slow-Lopressor	2009
Metyrapone	Cap 250 mg	Metopirone	2009
Mexiletine hydrochloride	Cap 50 mg & 200 mg	Mexitil	2008
Miconazole nitrate	Crn 2%	Multichem	2008
Midodrine	Tab 2.5 mg & 5 mg	Gutron	2009
Misoprostol	Tab 200 µg	Cytotec	2009
Moclobemide	Tab 150 mg & 300 mg	Apo-Moclobemide	2009
Morphine hydrochloride	Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml	RA-Morph RA-Morph RA-Morph RA-Morph	2009
Morphine sulphate	Inj 5 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Cap long-acting 10 mg, 30 mg, 60 mg, 100 mg & 200 mg Tab immediate release 10 mg & 20 mg	Mayne Mayne m-Eslon Sevredol	2009
Morphine tartrate	Inj 80 mg per ml, 1.5 ml & 5 ml	Mayne	2009
Naphazoline hydrochloride	Eye drops 0.1%	Naphcon Forte	2008
Naproxen	Tab 250 mg Tab 500 mg Tab long-acting 750 mg Tab long-acting 1000 mg	Noflam 250 Noflam 500 Naprosyn SR 750 Naprosyn SR 1000	2009 2008
Nevirapine	Oral suspension 10 mg per ml	Viramune Suspension	2009
Nicotinic acid	Tab 50 mg & 500 mg	Apo-Nicotinic Acid	2009
Nifedipine	Tab long-acting 20 mg	Nyefax Retard	2009
Nonoxynol-9	Jelly 2%	Gynol II	2008
Norethisterone	Tab 350 µg Tab 5 mg	Noriday 28 Primolut-N	2009 2008
Norfloxacin	Tab 400 mg	Arrow-Norfloxacin	2008
Nortriptyline	Tab 10 mg & 25 mg	Norpress	2008

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to September 2007

Generic Name	Presentation	Brand Name	Expiry Date*
Nystatin	Vaginal crm 100,000 u per 5 g with applicators	Nilstat	2009
	Oral liq 100,000 u per ml	Nilstat	2008
Ondansetron	Tab 4 mg & 8 mg Tab disp 4 mg & 8 mg	Zofran Zofran Zydys	2010
Oxytocin	Inj 5 iu per ml, 1 ml	Syntocinon	2009
	Inj 10 iu per ml, 1 ml	Syntocinon	
	Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml	Syntometrine	
Pamidronate disodium	Inj 3 mg per ml, 5 ml	Pamisol	2008
	Inj 3 mg per ml, 10 ml	Pamisol	
	Inj 6 mg per ml, 10 ml	Pamisol	
Paracetamol	Tab 500 mg	Panadol	2008
	Suppos 125 mg & 250 mg	Panadol	
	Oral liq 120 mg per 5 ml	Junior Parapaed	
	Oral liq 250 mg per 5 ml	Six Plus Parapaed	
Paracetamol with codeine	Tab 500 mg with 8 mg codeine	Codalgin	2008
Paroxetine hydrochloride	Tab 20 mg	Loxamine	2010
Pergolide	Tab 0.25 mg & 1 mg	Permax	2008
Perhexiline maleate	Tab 100 mg	Pexsig	2009
Pilocarpine	Eye drops 0.5%, 1%, 2%, 3%, 4% & 6%	Pilopt	2008
Poloxamer	Oral drops 10%	Coloxyl	2008
Potassium chloride	Tab long-acting 600 mg	Span-K	2009
	Inj 75 mg per ml, 10 ml	AstraZeneca	2008
	Inj 150 mg per ml, 10 ml	AstraZeneca	
Prednisone	Tab 1 mg, 2.5 mg, 5 mg & 20 mg	Apo-Prednisone	2008
Pregnancy tests - HCG urine	Cassette	MDS Quick Card	2009
Procaine penicillin	Inj 1.5 mega u	Cilicaine	2008
Promethazine hydrochloride	Tab 10 mg & 25 mg	Allersoothe	2008
Pyridoxine hydrochloride	Tab 50 mg	Apo-Pyridoxine	2009
Quinapril	Tab 5 mg, 10 mg & 20 mg	Accupril	2008
Quinapril with hydrochlorothiazide	Tab 10 mg with hydrochlorothiazide 12.5 mg	Accuretic 10	2008
	Tab 20 mg with hydrochlorothiazide 12.5 mg	Accuretic 20	
Quinine sulphate	Tab 200 mg	Q 200	2009
	Tab 300 mg	Q 300	
Ranitidine hydrochloride	Tab 150 mg & 300 mg	Arrow Ranitidine	2008
Roxithromycin	Tab 150 mg & 300 mg	Arrow-Roxithromycin	2009
Salbutamol with ipratropium bromide	Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg	Duolin	2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to September 2007

Generic Name	Presentation	Brand Name	Expiry Date*
Selegiline hydrochloride	Tab 5 mg	Apo-Selegiline	2009
Sodium chloride	Inj 0.9%, 5 ml & 10 ml	AstraZeneca	2009
Sodium cromoglycate	Nasal spray 4% Eye drops 2%	Rex Cromolux	2009 2008
Sulphasalazine	Tab 500 mg Tab EC 500 mg	Salazopyrin Salazopyrin EN	2009
Tar with triethanolamine lauryl sulphate and fluorescein	Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium	Pinetarsol	2008
Temazepam	Tab 10 mg	Normison	2008
Terbinafine	Tab 250 mg	Apo-Terbinafine	2008
Timolol maleate	Tab 10 mg	Apo-Timol	2009
Thiamine hydrochloride	Tab 50 mg	Apo-Thiamine	2009
Triamcinolone acetonide	Crn & Oint 0.02% Dental Paste USP 0.1%	Aristocort Oracort	2008
Triamcinolone acetonide with gramicidin, neomycin and nystatin	Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g Oint 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 µg per g	Kenacomb	2009
		Kenacomb	2008
Triazolam	Tab 125 µg Tab 250 µg	Hypam Hypam	2008
Trimethoprim	Tab 300 mg	TMP	2008
Trimipramine maleate	Cap 25 mg & 50 mg	Tripres	2008
Urea	Crn 10%	Nutraplus	2008
Ursodeoxycholic acid	Cap 300 mg	Actigall	2008
Vancomycin hydrochloride	Inj 50 mg per ml, 10 ml	Pacific	2008
Verapamil hydrochloride	Tab long-acting 120 mg	Verpamil SR	2008
Vincristine sulphate	Inj 1 mg per ml, 1 ml Inj 1 mg per ml, 2 ml	Mayne Mayne	2009
Vitamins	Tab (BPC cap strength)	Healtheries	2009
Vitamin B complex	Tab, strong, BPC	Apo-B-Complex	2009
Water	Purified for injection 20 ml	Multichem	2009
Zinc and castor oil	Oint BP	Multichem	2008
Zinc sulphate	Cap 220 mg	Zincaps	2008
Zopiclone	Tab 7.5 mg	Apo-Zopiclone	2008

September changes are in bold type

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

New Listings

Effective 1 September 2007

86	AZITHROMYCIN – Subsidy by endorsement a) Maximum of 2 tab per prescription b) Available on a PSO c) Subsidised only if prescribed for patients with uncomplicated urethritis or cervicitis proven or presumed to be due to Chlamydia trachomatis and their sexual contacts and prescription or PSO is endorsed accordingly. Tab 500 mg	9.90	2 OP	✓ Arrow-Azithromycin
104	METHADONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets). d) For methadone hydrochloride oral liquid refer, page 159 Tab 5 mg	2.10	10	✓ PSM
106	OXYCODONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable Inj 10 mg per ml, 1 ml Inj 10 mg per ml, 2 ml ‡ Oral liq 5 mg per 5 ml	14.40 28.80 11.20	5 5 250 ml	✓ OxyNorm ✓ OxyNorm ✓ OxyNorm

Prescribing Guideline

Prescribers should note that oxycodone is significantly more expensive than long-acting morphine sulphate and clinical advice suggests that it is reasonable to consider this as a second-line agent to be used after morphine.

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Changes to Restrictions

Effective 1 September 2007

113	ONDANSETRON – Hospital pharmacy [HP3] Retail pharmacy-Specialist
	a) Maximum of 12 tab per prescription; can be waived by Special Authority see SA0887 below
	b) Maximum of 6 tab per dispensing; can be waived by Special Authority see SA0887 below
	c) Not more than one prescription per month; can be waived by Special Authority see SA0887 below.
	Tab 4 mg 17.18 10 ✓Zofran
	Tab disp 4 mg 17.18 10 ✓Zofran Zydys
	Tab 8 mg 33.89 20 ✓Zofran
	Tab disp 8 mg 20.43 10 ✓Zofran Zydys

➔ **SA0887** Special Authority for Waiver of Rule

Initial application from any relevant practitioner. Approvals valid for 12 months where patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy.

Renewal from any relevant practitioner. Renewals valid for 12 months where patient is undergoing prolonged treatment with highly emetogenic chemotherapy and/or highly emetogenic radiation therapy for the treatment of malignancy.

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Subsidy and Manufacturer's Price

Effective 1 September 2007

29	METFORMIN HYDROCHLORIDE (↓ subsidy)			
	* Tab 500 mg	9.75	500	✓ Metomin
	* Tab 850 mg	8.00	250	✓ Metomin
47	WATER (↓ subsidy)			
	1) On a prescription or Practitioner's Supply Order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or			
	2) On a bulk supply order; or			
	3) When used in the extemporaneous compounding of eye drops.			
	Purified for inj 5 ml – Available on a PSO	9.31	50	✓ AstraZeneca
	Purified for inj 10 ml – Available on a PSO	10.38	50	✓ AstraZeneca
66	MALATHION (↓ subsidy)			
	Liq 0.5%.....	4.99 (5.80)	200 ml	AFT
67	HYDROCORTISONE BUTYRATE (↑ subsidy)			
	Scalp lotn 0.1%	7.52	100 ml OP	✓ Locoid
96	NITROFURANTOIN (↑ subsidy)			
	* Tab 50 mg	17.20	100	✓ Nifuran
	* Tab 100 mg	29.40	100	✓ Nifuran
116	LITHIUM CARBONATE (↑ subsidy)			
	Tab long-acting 400 mg	15.45	100	✓ Priadel
154	PHENYLEPHRINE HYDROCHLORIDE (↑ subsidy)			
	* Eye drops 0.12%	4.47	15 ml OP	✓ Prefrin

Changes to Section G: Safety Cap Medicines

Effective 1 September 2007

OXYCODONE HYDROCHLORIDE
Oral liq 5 mg per 5 ml.....OxyNorm

Changes to Sole Subsidised Supply

Effective 1 September 2007

For the list of new Sole Subsidised Supply products effective 1 September 2007 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 12-18.

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Delisted Items

Effective 1 September 2007

26	HYOSCINE N-BUTYLBROMIDE * Tab 10 mg	6.65 (10.85)	100	Buscopan
52	LISINAPRIL * Tab 5 mg	2.78 (4.91)	30	Prinivil
	* Tab 10 mg	3.16 (7.14)	30	Prinivil
	* Tab 20 mg	3.91 (10.10)	30	Prinivil
85	CEFTRIAXONE SODIUM – Hospital pharmacy [HP3] – Subsidy by endorsement a) Available on a PSO b) Subsidised only if prescribed for a dialysis or cystic fibrosis patient, or the treatment of confirmed ciprofloxacin-resistant gonorrhoea, or the treatment of suspected meningitis in patients who have a known allergy to penicillin, and the prescription or PSO is endorsed accordingly. Inj 250 mg	4.00	1	✓Rocephin IV
91	ACICLOVIR * Tab dispersible 200 mg	7.92 (10.00)	100	Acicvir
		7.13 (48.75)	90	Zovirax
	* Tab dispersible 400 mg	28.46 (36.00)	240	Acicvir
	* Tab dispersible 800 mg	21.09 (26.70)	100	Acicvir
91	VALACICLOVIR Tab 500 mg	1.58 (54.63)	10	Valtrex
		4.74 (163.80)	30	Valtrex
107	PAROXETINE HYDROCHLORIDE Tab 20 mg	5.90 (35.02)	30	Aropax
116	OLANZAPINE – Special Authority see SA0741– Retail pharmacy Tab 2.5 mg	54.72	30	✓Zyprexa
	Tab 5 mg	108.44	30	✓Zyprexa
	Tab 10 mg	219.10	30	✓Zyprexa
	Note – Zyprexa tab 2.5 mg, 5 mg and 10 mg 28 tablet pack size is still subsidised.			
117	TRIFLUOPERAZINE HYDROCHLORIDE Tab 5 mg	15.79 (17.77)	112	Stelazine Section 29 S29

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$

Per

Brand or
Generic Mnfr
✓ fully subsidised

Delisted Items - effective 1 September 2007 (continued)

125	CALCIUM FOLINATE Tab 15 mg – PCT – Hospital pharmacy [HP3]-Specialist.....	38.90 (55.60)	10		Leucovorin
152	BRIMONIDINE TARTRATE – Retail pharmacy-Specialist * Eye Drops 0.2%	8.95	5 ml OP	✓	Alphagan
175	GLUTEN FREE BREAD MIX – Special Authority see SA0722 – Hospital pharmacy [HP3] Powder	4.77 (7.63)	1,000 g OP		Bakels Gluten Free Bread Mix

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Items to be Delisted

Effective 1 October 2007

97	INFLUENZA VACCINE – Hospital pharmacy [Xpharm] Inj.....	75.00	10	✓Vaxigrip
----	--	-------	----	-----------

Effective 1 December 2007

64	CETOMACROGOL * Cream BP.....	2.80 (4.35)	500 g	IPW
66	MALATHION Liq 0.5%.....	4.99 (5.80)	200 ml	AFT
73	SODIUM CITRO-TARTRATE * Grans efl 4 g sachets	1.02 (2.40)	8	Ural

Note - the 28 pack size of Ural will continue to be available fully subsidised.

Effective 1 January 2008

97	INFLUENZA VACCINE – Hospital pharmacy [Xpharm] Inj.....	7.50	1	✓Fluvax
----	--	------	---	---------

Effective 1 March 2008

28	INSULIN ISOPHANE WITH INSULIN NEUTRAL ▲ Inj human with neutral insulin 100 u per ml	25.26	10 ml OP	✓Mixtard 50
	▲ Inj human with neutral insulin 100 u per ml, 3 ml	42.66	5	✓PenMix 10 ✓PenMix 20
55	ACEBUTOLOL * Tab 400 mg	27.63	100	✓ACB
116	PIMOZIDE – Retail pharmacy-Specialist Tab 4 mg	11.78	20	✓Orap Forte S29

Contracted Pharmaceutical Description	Brand	Price (\$) (ex man. excl. GST)	Per	DV Limit	DV Limit applies from	DV Pharmaceutical
---------------------------------------	-------	--------------------------------	-----	----------	-----------------------	-------------------

Section H changes to Part II

Effective 1 September 2007

AZITHROMYCIN

Tab 500 mg.....	Arrow-Azithromycin	9.90	2	1%	Nov-07	Zithromax
-----------------	---------------------------	------	---	----	--------	-----------

METHADONE HYDROCHLORIDE

Tab 5 mg.....	PSM	2.10	10	1%	Nov-07	Pallidone
---------------	------------	------	----	----	--------	-----------

OXYCODONE HYDROCHLORIDE

Inj 10 mg per ml, 1 ml.....	OxyNorm	14.40	5	1%	Nov-07	(B)
Inj 10 mg per ml, 2 ml.....	OxyNorm	28.80	5	1%	Nov-07	(B)
Oral liq 5 mg per 5 ml.....	OxyNorm	11.20	250 ml	1%	Nov-07	(B)

Effective 1 August 2007

EXEMESTANE

Tab 25 mg.....	Aromasin	175.00	30			
----------------	----------	--------	----	--	--	--

FLUOROURACIL SODIUM (↓ price and addition of HSS)

Inj 25 mg per ml 100 ml.....	Mayne	13.55	1	1%	Oct-07	(B)
Inj 50 mg per ml, 10 ml.....	Fluorouracil Ebewe	4.95	1	1%	Oct-07	Mayne
Inj 50 mg per ml, 20 ml.....	Fluorouracil Ebewe	8.60	1	1%	Oct-07	Mayne
Inj 50 mg per ml, 50 ml.....	Fluorouracil Ebewe	21.50	1	1%	Oct-07	Mayne
Inj 50 mg per ml, 100 ml.....	Fluorouracil Ebewe	43.00	1	1%	Oct-07	(B)

Note – Mayne’s brand of Fluorouracil sodium inj 50 mg per ml, 10 ml, 20 ml and 50 ml to be delisted 1 October 2007

GABAPENTIN (↓ price)

Cap 100 mg.....	Neurontin	15.67	100			
Cap 300 mg.....	Neurontin	47.00	100			
Cap 400 mg.....	Neurontin	62.66	100			
Tab 600 mg.....	Neurontin	79.79	100			

HYDROXYCOBALAMIN (Delisted effective 1 August 2007)

Inj 1 mg per ml, 1 ml.....	Neo-Cytamen	10.84	3			
----------------------------	-------------	------------------	---	--	--	--

IBUPROFEN

Oral liq 100 mg per 5 ml.....	Fenpaed	3.49	200 ml	1%	Oct-07	Nurofen
-------------------------------	----------------	------	--------	----	--------	---------

LOPINAVIR WITH RITONAVIR

Tab 200 mg with ritonavir 50 mg.....	Kaletra	735.00	120			
Oral liq 80 mg with ritonavir 20 mg per ml.....	Kaletra	735.00	300 ml			

MESNA (addition of HSS)

Inj 100 mg per ml, 4 ml.....	Uromitexan	109.63	15	1%	Oct-07	(B)
Inj 100 mg per ml, 10 ml.....	Uromitexan	251.73	15	1%	Oct-07	(B)

Products with Hospital Supply Status (HSS) are in **bold**.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description	Brand	Price (\$) (ex man. excl. GST)	Per	DV Limit	DV Limit applies from	DV Pharmaceutical
---------------------------------------	-------	--------------------------------	-----	----------	-----------------------	-------------------

Section H changes to Part II - effective 1 August 2007 (continued)

OXYCODONE HYDROCHLORIDE

Tab controlled-release 5 mg	OxyContin	7.51	20			
-----------------------------------	-----------	------	----	--	--	--

ZIPRASIDONE

Cap 20 mg	Zeldox	87.88	60			
Cap 40 mg	Zeldox	164.78	60			
Cap 60 mg	Zeldox	247.17	60			
Cap 80 mg	Zeldox	329.56	60			

Index

Pharmaceuticals and brands

A		
ACB	24	
Acebutolol.....	24	
Aciclovir	22	
Acicvir	22	
Alphagan	23	
Aromasin	25	
Aropax.....	22	
Arrow-Azithromycin	19, 25	
Azithromycin.....	19, 25	
B		
Bakels Gluten Free Bread Mix	23	
Brimonidine tartrate.....	23	
Buscopan	22	
C		
Calcium folinate	23	
Ceftriaxone sodium	22	
Cetomacrogol	24	
E		
Exemestane	25	
F		
Fenpaed.....	25	
Fluorouracil Ebewe.....	25	
Fluorouracil sodium.....	25	
Fluvax.....	24	
G		
Gabapentin	25	
Gluten free bread mix	23	
H		
Hydrocortisone butyrate	21	
Hydroxocobalamin	25	
Hyoscine N-butylbromide	22	
I		
Ibuprofen	25	
Influenza vaccine.....	24	
Insulin isophane with insulin neutral.....	24	
K		
Kaletra	25	
L		
Leucovorin.....	23	
Lisinopril.....	22	
Lithium carbonate	21	
Locoid	21	
Lopinavir with ritonavir	25	
M		
Malathion.....	21, 24	
Mesna	25	
Metformin hydrochloride	21	
Methadone hydrochloride.....	19, 25	
Metomin	21	
Mixtard 50	24	
N		
Neo-Cytamen.....	25	
Neurontin.....	25	
Nifuran.....	21	
Nitrofurantoin	21	
O		
Olanzapine	22	
Ondansetron	20	
Orap Forte.....	24	
Oxycodone hydrochloride.....	19, 21, 25, 26	
OxyContin	26	
OxyNorm	19, 21, 25	
P		
Paroxetine hydrochloride	22	
PenMix 10	24	
PenMix 20	24	
Phenylephrine hydrochloride	21	
Pimozide.....	24	
Prefrin.....	21	
Priadel	21	
Prinivil.....	22	
R		
Rocephin IV	22	
S		
Sodium citro-tartrate	24	
Stelazine Section 29.....	22	
T		
Trifluoperazine hydrochloride.....	22	
U		
Ural.....	24	
Uromitexan	25	
V		
Valaciclovir	22	
Valtrex	22	
Vaxigrip	24	
W		
Water.....	21	
Z		
Zeldox	26	
Ziprasidone	26	
Zofran	20	
Zofran Zydis.....	20	
Zovirax.....	22	
Zyprexa.....	22	



While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

Pharmaceutical Management Agency
Level 14 Cigna House, 40 Mercer Street
PO Box 10 254 Wellington, New Zealand
Telephone 64 4 460 4990 Facsimile 64 4 460 4995
Freephone information line (9am - 4pm weekdays) 0800 66 00 50
www.pharmac.govt.nz